What type of study is this?

September 16, 2025

Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

View Full Paper

Ask AI

Bookmark

Authors

Phase IB NABUCCO study analyzes patient responses by molecular subtype, showing distinct outcomes based on treatment groups.

Responders had a distinct fraction of molecular subtypes compared to non-responders, highlighting treatment effectiveness.
In the study, 5 patients were classified per consensus, with 4 patients under TCGA classification for treatment responses.
There were no neuro-endocrine subtypes found in the patient cohort, indicating specific limitations in molecular diversity.
Treatment dynamics involving ipilimumab and nivolumab demonstrate the importance of biomarker analysis in therapy outcomes.

Stockem et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 16, 2025

View Full Paper

Ask AI

Bookmark

Authors

Phase IB NABUCCO study analyzes patient responses by molecular subtype, showing distinct outcomes based on treatment groups.

Responders had a distinct fraction of molecular subtypes compared to non-responders, highlighting treatment effectiveness.
In the study, 5 patients were classified per consensus, with 4 patients under TCGA classification for treatment responses.
There were no neuro-endocrine subtypes found in the patient cohort, indicating specific limitations in molecular diversity.
Treatment dynamics involving ipilimumab and nivolumab demonstrate the importance of biomarker analysis in therapy outcomes.

Stockem et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark